Search Results

CD19-directed CAR T-cell therapies for relapsed/refractory B-cell lymphomas. “Given the unprecedented bench-to-bedside clinical success, research and development aimed at refining our existing immunotherapies is proceeding at a very rapid pace,” said

The advent of targeted agents for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has led to significant improvements in overall survival (OS), progression-free survival (PFS), and quality of life

PSA era . Int J Radiat Oncol Biol Phys 2003 ; 57 : 915 – 928 . 5 Sylvester JE Blasko JC Grimm PD . Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle

presented with an isolated central nervous system (CNS) relapse after standard imatinib therapy with good response. Further treatment options, and monitoring of disease response, are discussed. Case Report A 24-year-old otherwise healthy Caucasian

The landscape of relapsed chronic lymphocytic leukemia (CLL) has changed dramatically over the past few years primarily due to changes in the frontline setting. During the NCCN 2021 Virtual Annual Conference, Jennifer R. Brown, MD, PhD, Director

plasma levels and nephrotoxicity . J Clin Oncol 1987 ; 5 : 304 – 309 . 95. Baniel J Foster RS Gonin R . Late relapse of testicular cancer . J Clin Oncol 1995 ; 13 : 1170 – 1176 . 96. George DW Foster RS Hromas RA . Update on

CAR T cells continue to show impressive activity in relapsed/refractory non-Hodgkin lymphoma, with durable complete responses in a significant percentage of patients with chemorefractory disease. According to Andrew D. Zelenetz, MD, PhD, Medical

-MTX) backbone, have demonstrated efficacy in the treatment of newly diagnosed and relapsed or refractory (R/R) PCNSL, but currently there is no consensus on the optimal treatment of these patients. Very few prospective randomized controlled studies have been

relapses are common. 7 - 10 After TMT, most patients undergo surveillance for at least 5 years; however, the surveillance recommendations vary considerably and are often empiric in nature. 6 , 10 Relapses seem to be related to the sensitivity of the

Hope remains for patients with acute lymphoblastic leukemia (ALL)—hope to extend life and hope to minimize relapse—according to Patrick A. Brown, MD, and Bijal Shah, MD, who discussed the latest treatment options for ALL during their presentations